Saturday 17 October 2026
Export ANAB’s income statement to Excel — free account
AnaptysBio, Inc.
ANAB Healthcare Biotechnology
AnaptysBio, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $234.6 million, up 157.0% from fiscal 2024. In the quarter to March 2026, revenue fell 7.98%, EPS fell 43.8% and free cash flow fell 141.6%, each against the same quarter a year earlier. Revenue growth for three consecutive years.
46.61
2.10
−4.31%
Follow ANAB
| Mar '26 | Dec '25 | Sep '25 | Jun '25 | Older periods | |
|---|---|---|---|---|---|
Piotroski F-Score |
6 | 5 | 3 | 4 |
+8 more TTM periods Free account |
| (114.55%) | (24.49%) | (308.02%) | 760.85% | ||
| (7.13%) | (3.12%) | (19.99%) | (34.77%) | ||
ROIC |
0.00% | 0.00% | 0.00% | 0.00% | |
Return on Tangible Assets |
(9.72%) | (4.23%) | (28.78%) | (51.39%) | |
Average Days of Receivables |
40.44 | 52.66 | 163.01 | 63.47 | |
Free Cash Flow per Share |
0.15 | 0.68 | (5.22) | (4.45) | |
Free Cash Flow |
4.41 | 19.61 | (145.32) | (128.08) | |
Capital Expenditures |
(0.07) | (0.09) | (0.35) | (0.37) | |
| Other line items | |||||
Cash ROIC |
1.47% | 5.62% | (66.19%) | (57.96%) | |
Accounts Receivable Turnover |
10.65 | 6.29 | 3.86 | 8.10 | |
Accounts Payable Turnover |
0.00 | 0.00 | 0.00 | 0.00 | |
Average Days of Payables |
0.00 | 0.00 | 0.00 | 0.00 | |
Tax Rate |
0.01 | 0.01 | 0.00 | 0.00 | |
Research and Development Expense of Revenue |
55.42% | 57.96% | 90.28% | 133.00% | |
Selling, General and Administrative Expense of Revenue |
27.03% | 21.63% | 26.64% | 36.94% | |
Share Based Compensation of Revenue |
17.69% | 15.38% | 21.10% | 28.24% | |
Operating CF/Net income |
(0.17) | (1.49) | 1.71 | 0.96 | |
Depreciation/Fixed assets |
(0.51) | (1.69) | (2.85) | (3.52) | |
Capex/Depreciation |
0.11 | 0.04 | 0.08 | 0.06 | |
Revenue per Share |
8.10 | 8.16 | 6.09 | 4.28 | |
Operating CF per Share |
0.16 | 0.68 | (5.21) | (4.43) | |
Capex per Share |
0.00 | 0.00 | (0.01) | (0.01) | |
Capex to Sales |
0.00 | 0.00 | 0.00 | 0.00 |
Columns are period end dates